Literature DB >> 24509324

Plasma factor XI and XII activity in patients with slow coronary flow.

Muhsin Türkmen1, Cüneyt Toprak, Göksel Açar, Mehmet M Tabakçi, Halil I Durmuş, Mehmet V Yazicioğlu, Ali M Esen, Irfan Barutcu.   

Abstract

The exact pathophysiology of slow coronary flow (SCF) phenomenon, characterized by delayed opacification of coronary arteries during coronary angiography, is still unknown, although endothelial dysfunction, inflammation, vasomotor disorders and atherosclerosis are shown. The present study was conducted to investigate whether there is a coagulation pathway abnormality in patients with SCF measuring plasma factor XI and XII activity. The study included 55 patients with angiographically proven SCF (group I) and 40 individuals with normal coronary flow (NCF, group II). Baseline demographic properties were similar in both groups. Echocardiographic parameters were also similar in patients with SCF and NCF. Factor XI activity was significantly higher in group I when compared with group II. Factor XII activity was also significantly higher in group I when compared with group II (108.9 ± 19 vs. 98.8 ± 20, P = 0.018 and 131.2 ± 17 vs. 119.1 ± 16, P = 0.001, respectively). We conclude that SCF phenomenon appears to be associated with enhanced procoagulant state, which may support the role of inflammation and atherosclerosis in the pathogenesis of this phenomenon.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 24509324     DOI: 10.1097/MBC.0000000000000061

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  1 in total

1.  The relationship between eosinophilia and slow coronary flow.

Authors:  Yakup Altas; Ertugrul Kurtoglu; Baris Yaylak; Erkan Baysal; Berzal Ucaman; Hasan Murat Ugurlu; Mehmet Zülkif Karahan; Bernas Altintas; Mehmet Sahin Adiyaman; İlyas Kaya; Umut Erdolu; Kaya Ozen; Cayan Cakir; Utkan Sevuk
Journal:  Ther Clin Risk Manag       Date:  2015-08-12       Impact factor: 2.423

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.